A phase III study of JHL1101 (Rituximab Biosimilar) in patients with Non-Hodgkin's Lymphoma

Trial Profile

A phase III study of JHL1101 (Rituximab Biosimilar) in patients with Non-Hodgkin's Lymphoma

Planning
Phase of Trial: Phase III

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Rituximab (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Jul 2017 According to a JHL Biotech media release, Clinical Trial Application (CTA) for use of JHL1101 in phase III clinical trial in Non-Hodgkins Lymphoma patients is under review by the China Food and Drug Administration (CFDA) Center for Drug Evaluation (CDE).
    • 11 Apr 2017 New trial record
    • 04 Apr 2017 According to a JHL Biotech media release, the Clinical Trial Application (CTA) for the use of JHL1101 in phase III clinical trial in Non-Hodgkin's Lymphoma patients has been accepted by the China Food and Drug Administration (CFDA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top